A randomized, double‐blind placebo‐controlled phase I clinical study on safety and efficacy of the G‐Rup® syrup (a mixture of ginger extract and honey) in symptomatic treatment of knee osteoarthritis. (30th November 2022)
- Record Type:
- Journal Article
- Title:
- A randomized, double‐blind placebo‐controlled phase I clinical study on safety and efficacy of the G‐Rup® syrup (a mixture of ginger extract and honey) in symptomatic treatment of knee osteoarthritis. (30th November 2022)
- Main Title:
- A randomized, double‐blind placebo‐controlled phase I clinical study on safety and efficacy of the G‐Rup® syrup (a mixture of ginger extract and honey) in symptomatic treatment of knee osteoarthritis
- Authors:
- Afshar, Fariba
Abdolahi, Nafiseh
Amin, Gholamreza
Esmaily, Hadi
Ziayie, Shadi
Azimi, Saeed
Darvishi, Behnam
Afshar, Shima - Abstract:
- Abstract: What is known and Objectives: Present study evaluated the safety profile and efficacy of G‐Rup® syrup (100 mg/ml ginger extract plus 150 mg/ml honey) in symptomatic treatment of knee osteoarthritis (OA). Methods: Patients diagnosed with knee OA were randomly assigned (1:1) to receive either of a 30 ml twice daily regimen of G‐Rup® syrup or placebo over a 12‐week period. Primary endpoints of the study comprised of an improvement in the joint's stiffness, physical functioning and pain score, assessed by WOMAC questionnaire and the visual analog scale (VAS). Secondary objectives comprised of safety and tolerability of the syrup by patients. Results and discussion: The 30 ml twice‐daily regimen of G‐Rup® syrup was safe and well tolerated by patients. Moreover, in whole studied time points, treatment with G‐Rup® syrup could significantly Power the VAS score ( p < 0.001) whereas improving WOMAC total score ( p < 0.001) and pain ( p < 0.001), physical functioning ( p < 0.001), and stiffness sub‐scores ( p = 0.006) compared to the placebo receiving group. What is new and Conclusion: Based on obtained results, the G‐Rup® syrup, composed of a combination of honey and ginger, may be a proper supplementary choice, along with routine therapeutic regimens, for improvement of symptomatic treatment of OA. Abstract : Present study represents significant anti‐arthritis rheumatoid effects of G‐Rup® syrup G‐Rup® syrup (100 mg/ml ginger extract plus 150 mg/ml honey) in patients.Abstract: What is known and Objectives: Present study evaluated the safety profile and efficacy of G‐Rup® syrup (100 mg/ml ginger extract plus 150 mg/ml honey) in symptomatic treatment of knee osteoarthritis (OA). Methods: Patients diagnosed with knee OA were randomly assigned (1:1) to receive either of a 30 ml twice daily regimen of G‐Rup® syrup or placebo over a 12‐week period. Primary endpoints of the study comprised of an improvement in the joint's stiffness, physical functioning and pain score, assessed by WOMAC questionnaire and the visual analog scale (VAS). Secondary objectives comprised of safety and tolerability of the syrup by patients. Results and discussion: The 30 ml twice‐daily regimen of G‐Rup® syrup was safe and well tolerated by patients. Moreover, in whole studied time points, treatment with G‐Rup® syrup could significantly Power the VAS score ( p < 0.001) whereas improving WOMAC total score ( p < 0.001) and pain ( p < 0.001), physical functioning ( p < 0.001), and stiffness sub‐scores ( p = 0.006) compared to the placebo receiving group. What is new and Conclusion: Based on obtained results, the G‐Rup® syrup, composed of a combination of honey and ginger, may be a proper supplementary choice, along with routine therapeutic regimens, for improvement of symptomatic treatment of OA. Abstract : Present study represents significant anti‐arthritis rheumatoid effects of G‐Rup® syrup G‐Rup® syrup (100 mg/ml ginger extract plus 150 mg/ml honey) in patients. Treatment with G‐Rup® syrup could significantly lower the VAS score ( p < 0.001) whereas improving WOMAC total score ( p < 0.001) and pain ( p < 0.001), physical functioning ( p < 0.001), and stiffness sub‐scores ( p = 0.006) compared to the placebo receiving group. … (more)
- Is Part Of:
- Journal of clinical pharmacy and therapeutics. Volume 47:Number 12(2022)
- Journal:
- Journal of clinical pharmacy and therapeutics
- Issue:
- Volume 47:Number 12(2022)
- Issue Display:
- Volume 47, Issue 12 (2022)
- Year:
- 2022
- Volume:
- 47
- Issue:
- 12
- Issue Sort Value:
- 2022-0047-0012-0000
- Page Start:
- 2295
- Page End:
- 2301
- Publication Date:
- 2022-11-30
- Subjects:
- ginger -- honey -- integrative medicine -- osteoarthritis -- pain -- Persian medicine -- WOMAC -- Zingiber officinale
Clinical pharmacology -- Periodicals
Chemotherapy -- Periodicals
615 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2710 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/jcpt.13812 ↗
- Languages:
- English
- ISSNs:
- 0269-4727
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.685000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24865.xml